Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges

Neuroscience & Biobehavioral Reviews(2020)10.1016/j.neubiorev.2020.04.024Source: DataRank Database

Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges is a research paper published in Neuroscience & Biobehavioral Reviews (2020). On theSindex it has a DataRank of 0. It has been cited 54 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access54 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 2.73)OA: greenTopics (30)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (3)

Amy Hauck Newman ORCID,Zheng‐Xiong Xi ORCID,Ewa Galaj ORCID

Live enrichment

PubMed:32376243 PMC:PMC7252042 OpenAlex:https://openalex.org/W3021263230

National Institute on Drug Abuse

Grant: Z1A DA000620-02

Intramural NIH HHS

Grant: ZIA DA000620

Intramural NIH HHS

Grant: Z99 DA999999

FWCI

2.73

Citation Percentile

0.9%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

greenLicense: https://www.elsevier.com/legal/tdmrep-license

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7252042

publisherhttps://api.elsevier.com/content/article/PII:S0149763420303894?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0149763420303894?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.neubiorev.2020.04.024

Fields of Study

Neurotransmitter Receptor Influence on BehaviorOpioid Use Disorder TreatmentNeuropeptides and Animal Physiology

MeSH Terms

Drug DevelopmentAnalgesics, OpioidAnimalsBuprenorphineMethadoneOpioid-Related DisordersUnited StatesReceptors, Dopamine D3

Keywords

Opioid use disorderBuprenorphineOpioidMedicineMethadone(+)-NaloxoneDopamine receptor D3Substance abusePsychiatryPharmacologyDopamine receptorDopamineInternal medicineReceptorAnalgesiaRelapseAddictionDopamine D3 ReceptorDrug Self-administration

Sustainable Development Goals

SDG 0: Good health and well-being